<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>In 1965 Olav Egeberg (1916-77) presented the first report that linked a defined, hereditary defect in the control of blood coagulation to <z:e sem="disease" ids="C0087086" disease_type="Disease or Syndrome" abbrv="">thrombotic disease</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>Having examined a family in which several members had sustained <z:hpo ids='HP_0004936'>venous thrombosis</z:hpo>, he demonstrated that antithrombin activity was clearly subnormal in the affected members </plain></SENT>
<SENT sid="2" pm="."><plain><z:chebi fb="5" ids="28304">Heparin</z:chebi> cofactor activity was also subnormal in these persons </plain></SENT>
<SENT sid="3" pm="."><plain>This supported the hypothesis that the two activities might reside in a single protein </plain></SENT>
<SENT sid="4" pm="."><plain>The condition was inherited as an <z:hpo ids='HP_0000006'>autosomal dominant</z:hpo> trait </plain></SENT>
<SENT sid="5" pm="."><plain>Egeberg's publication initiated <z:hpo ids='HP_0100724'>thrombophilia</z:hpo> as a rewarding research area, and also as an important clinical discipline </plain></SENT>
</text></document>